TUMOR SOFTENING TREATMENT FOR BLADDER CANCER
Scientists in
Manchester have identified a protein that could help doctors decide which
bladder cancer patients would benefit from a treatment that makes radiotherapy
more effective, according to a study published in the British
Journal of Cancer (BJC)
This fascinating new
finding could help doctors adapt their treatments to patients with bladder
cancer," said Nell Barrie, Cancer Research UK
The team from The
University of Manchester, funded by the Medical Research Council, found that
patients whose bladder tumor had high levels of a protein, called 'HIF-1α',
were more likely to benefit from having carbogen -- oxygen mixed with carbon
dioxide gas -- and nicotinamide tablets at the same time as their radiotherapy.
The treatment, called 'CON', makes radiotherapy more effective.
By comparing levels of
HIF-1α in tissue samples from 137 patients who had radiotherapy on its own or
with CON, the researchers found the protein predicted which patients benefited
from having CON. High levels of the protein were linked to better survival from
the disease when patients had radiotherapy and CON. Patients with low protein
levels did not benefit from having CON with their radiotherapy.
The HIF-1α protein
indicates low oxygen levels in tumor cells -- a state known as 'hypoxia'. The
CON treatment works by adding oxygen to the oxygen-deprived tumor cells which
makes them more sensitive to the radiotherapy.
Study author,
Professor Catharine West, a Cancer Research UK scientist at The University of
Manchester, said: "Although we have another biomarker that can predict
responsiveness to CON and radiotherapy in bladder cancer patients, our findings
tell us a bit more about the characteristics of bladder cancer tumors and how
they may respond to this treatment."
"But we desperately
need to do more work to find ways to treat those patients who won't see as much
benefit from this.
"And it's exactly
this type of vital research that we and other scientists will be doing at the
Manchester Cancer Research Centre -- bringing together a wide range of
expertise to revolutionise cancer treatment."
Around 65 people are
diagnosed with bladder cancer in Manchester every year. There are around 25
deaths from the disease every year.
Nell Barrie, senior
science communications manager at Cancer Research UK, said: "This
fascinating new finding could help doctors adapt their treatments to patients with
bladder cancer as well as shedding more light on the disease.
"Deaths from
bladder cancer are falling in the UK, but more work needs to be done so that
this trend continues. More research is needed to helps us find new and better
ways to fight bladder cancer."
Comments
Post a Comment